{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=39", "query": { "intervention": "pembrolizumab", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 837, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=38&page_size=10" }, "source": "local", "last_synced_at": "2026-10-28T12:54:07.916Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05761223", "title": "A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab", "type": "DRUG" }, { "name": "Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)", "type": "DRUG" }, { "name": "Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)", "type": "DRUG" }, { "name": "Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)", "type": "DRUG" }, { "name": "Phase Ia dose-escalation part of FB849 Monotherapy", "type": "DRUG" }, { "name": "Phase Ib dose-expansion of FB849 monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "1ST Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2023-12-13", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-10-15T04:55:30.403Z", "location_count": 5, "location_summary": "Cleveland, Ohio • Dallas, Texas • San Antonio, Texas + 2 more", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05761223" }, { "nct_id": "NCT05394103", "title": "Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" }, { "name": "Q901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qurient Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-08-30", "completion_date": "2026-08-30", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-08-04T02:54:06.416Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05394103" }, { "nct_id": "NCT06415487", "title": "ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "ACE2016", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acepodia Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-08-22", "completion_date": "2027-03-27", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-16T08:12:57.944Z", "location_count": 4, "location_summary": "San Diego, California • Denver, Colorado • Nashville, Tennessee + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06415487" }, { "nct_id": "NCT05785754", "title": "DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "DCSZ11", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tebentafusp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DynamiCure Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2023-06-28", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-10-22T01:56:49.027Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785754" }, { "nct_id": "NCT05970497", "title": "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Cutaneous Melanoma", "Melanoma Stage III", "Melanoma Stage IV" ], "interventions": [ { "name": "KB707", "type": "BIOLOGICAL" }, { "name": "KEYTRUDA ®( Pembrolizumab)", "type": "DRUG" }, { "name": "Opdualag", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Krystal Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2023-10-31", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-15T06:13:24.287Z", "location_count": 15, "location_summary": "Los Angeles, California • Rancho Santa Margarita, California • Weston, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Santa Margarita", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05970497" }, { "nct_id": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma", "Head and Neck Cancer", "Malignant Melanoma", "Small Cell and Non-small Cell Lung Cancer", "Solid Tumor", "Squamous Cell Carcinoma of Larynx", "Squamous Cell Carcinoma of Nasopharynx", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of Other Specified Sites of Skin" ], "interventions": [ { "name": "Chemotherapy Prior to RAPA-201 Therapy", "type": "DRUG" }, { "name": "Pembrolizumab (PD-1 Blocking Antibody)", "type": "DRUG" }, { "name": "RAPA-201 Rapamycin Resistant T Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Rapa Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-08-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-10-12T00:15:20.862Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144698" }, { "nct_id": "NCT06493552", "title": "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Muscle-Invasive Bladder Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "SEphB4-HSA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vasgene Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2025-03-15", "completion_date": "2034-08", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-07-28T23:10:10.532Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06493552" }, { "nct_id": "NCT05784688", "title": "Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Biliary Tract Cancer", "Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "Solid Tumor" ], "interventions": [ { "name": "TU2218 + KEYTRUDA® (Pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TiumBio Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2023-03-10", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-10-28T12:54:07.916Z", "location_count": 3, "location_summary": "San Antonio, Texas • Tyler, Texas • Spokane, Washington", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Tyler", "state": "Texas" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05784688" }, { "nct_id": "NCT05020860", "title": "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Female", "Breast Cancer Invasive", "Breast Cancer Stage II", "Breast Cancer Stage III", "Breast Neoplasm", "Estrogen Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Hormone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab/Trastuzumab/Hyaluronidase-zzxf", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2023-04-18", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-10-15T05:53:22.607Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020860" }, { "nct_id": "NCT04990921", "title": "Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Palliative Radiation and Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2021-09-02", "completion_date": "2031-07-01", "has_results": false, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-10-14T04:15:19.643Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990921" } ] }